235 related articles for article (PubMed ID: 34981419)
1. Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis.
Zhong P; Zeng H; Huang M; Fu W; Chen Z
Endocrine; 2022 Mar; 75(3):718-724. PubMed ID: 34981419
[TBL] [Abstract][Full Text] [Related]
2. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
Rubino DM; Greenway FL; Khalid U; O'Neil PM; Rosenstock J; Sørrig R; Wadden TA; Wizert A; Garvey WT;
JAMA; 2022 Jan; 327(2):138-150. PubMed ID: 35015037
[TBL] [Abstract][Full Text] [Related]
3. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D; Abrahamsson N; Davies M; Hesse D; Greenway FL; Jensen C; Lingvay I; Mosenzon O; Rosenstock J; Rubio MA; Rudofsky G; Tadayon S; Wadden TA; Dicker D;
JAMA; 2021 Apr; 325(14):1414-1425. PubMed ID: 33755728
[TBL] [Abstract][Full Text] [Related]
4. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Davies M; Færch L; Jeppesen OK; Pakseresht A; Pedersen SD; Perreault L; Rosenstock J; Shimomura I; Viljoen A; Wadden TA; Lingvay I;
Lancet; 2021 Mar; 397(10278):971-984. PubMed ID: 33667417
[TBL] [Abstract][Full Text] [Related]
5. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
Wadden TA; Bailey TS; Billings LK; Davies M; Frias JP; Koroleva A; Lingvay I; O'Neil PM; Rubino DM; Skovgaard D; Wallenstein SOR; Garvey WT;
JAMA; 2021 Apr; 325(14):1403-1413. PubMed ID: 33625476
[TBL] [Abstract][Full Text] [Related]
6. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
Kadowaki T; Isendahl J; Khalid U; Lee SY; Nishida T; Ogawa W; Tobe K; Yamauchi T; Lim S;
Lancet Diabetes Endocrinol; 2022 Mar; 10(3):193-206. PubMed ID: 35131037
[TBL] [Abstract][Full Text] [Related]
7. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.
Kosiborod MN; Bhatta M; Davies M; Deanfield JE; Garvey WT; Khalid U; Kushner R; Rubino DM; Zeuthen N; Verma S
Diabetes Obes Metab; 2023 Feb; 25(2):468-478. PubMed ID: 36200477
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Moiz A; Levett JY; Filion KB; Peri K; Reynier P; Eisenberg MJ
Am J Cardiol; 2024 Jul; 222():121-130. PubMed ID: 38679221
[TBL] [Abstract][Full Text] [Related]
9. Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH; Batterham RL; Calanna S; Davies M; Van Gaal LF; Lingvay I; McGowan BM; Rosenstock J; Tran MTD; Wadden TA; Wharton S; Yokote K; Zeuthen N; Kushner RF;
N Engl J Med; 2021 Mar; 384(11):989-1002. PubMed ID: 33567185
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis.
Dorneles G; Algeri E; Lauterbach G; Pereira M; Fernandes B
Exp Clin Endocrinol Diabetes; 2024 Jun; 132(6):316-327. PubMed ID: 38599612
[TBL] [Abstract][Full Text] [Related]
11. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
Garvey WT; Batterham RL; Bhatta M; Buscemi S; Christensen LN; Frias JP; Jódar E; Kandler K; Rigas G; Wadden TA; Wharton S;
Nat Med; 2022 Oct; 28(10):2083-2091. PubMed ID: 36216945
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.
Wharton S; Calanna S; Davies M; Dicker D; Goldman B; Lingvay I; Mosenzon O; Rubino DM; Thomsen M; Wadden TA; Pedersen SD
Diabetes Obes Metab; 2022 Jan; 24(1):94-105. PubMed ID: 34514682
[TBL] [Abstract][Full Text] [Related]
13. Once-weekly semaglutide for obesity or overweight: A systematic review and meta-analysis.
He K; Guo Q; Zhang H; Xi W; Li J; Jing Z
Diabetes Obes Metab; 2022 Apr; 24(4):722-726. PubMed ID: 34866313
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
[TBL] [Abstract][Full Text] [Related]
15. High-Dose Once-Weekly Semaglutide: A New Option for Obesity Management.
Bradley CL; McMillin SM; Hwang AY; Sherrill CH
Ann Pharmacother; 2022 Aug; 56(8):941-950. PubMed ID: 34706581
[TBL] [Abstract][Full Text] [Related]
16. Clinical review of subcutaneous semaglutide for obesity.
Phillips A; Clements JN
J Clin Pharm Ther; 2022 Feb; 47(2):184-193. PubMed ID: 34964141
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological profile of once-weekly injectable semaglutide for chronic weight management.
Lau DCW; Batterham RL; le Roux CW
Expert Rev Clin Pharmacol; 2022 Mar; 15(3):251-267. PubMed ID: 35466848
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-A systematic review and meta-analysis of randomized controlled trials.
Kommu S; Berg RL
Obes Rev; 2024 Jun; ():e13792. PubMed ID: 38923272
[TBL] [Abstract][Full Text] [Related]
19. Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety.
Müllertz ALO; Sandsdal RM; Jensen SBK; Torekov SS
Obes Rev; 2024 May; 25(5):e13717. PubMed ID: 38463003
[TBL] [Abstract][Full Text] [Related]
20. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A
Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
